KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing

KalVista Pharmaceuticals, Inc.

Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.
CEO transition: Benjamin Palleiko appointed CEO, succeeding prior CEO as part of commercial preparation.
Closed underwritten offering netting ~$150.1M from 7.0M shares and 3.5M pre-funded warrants at $15.25/share.
Net loss $29.0M ($0.84/sh) for fiscal Q3 ended Jan 31, 2024, vs $21.3M ($0.75) YoY; cash $75.6M.
NDA submission on track for H1 2024; UK MHRA granted Innovation Passport for sebetralstat.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KalVista Pharmaceuticals, Inc. reported the fiscal quarter ended January 31, 2024 results: net income $29.0 million, EPS $(0.84) per weighted average basic and diluted share.

Period: the fiscal quarter ended January 31, 2024
Net income: $29.0 million
EPS: $(0.84) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.